Suitable for use as an immunotoxin against human B cell leukaemias and lymphomas.
| Institute |
|---|
| University College London (UCL) |
| Cat. #: | 151335 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Cell signaling and signal transduction;Immunology;Stem cell biology |
| Application: | FACS ; IHC ; IF |
| Target: | CD22 |
| Reactivity: | Human |
| Clone: | RFB-4 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | Establishing origin of B cell malignancies, especially discriminating between immature (bone marrow type) and peripheral B cell leukaemias and lymphomas. Suitable for use as an immunotoxin against human B cell leukaemias and lymphomas. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Molecular weight: | 153 kDa |
| Immunogen: | Tonsil lymphocytes |
| Myeloma used: | P3X63Ag8 |
| Target background: | Establishing origin of B cell malignancies, especially discriminating between immature (bone marrow type) and peripheral B cell leukaemias and lymphomas. Suitable for use as an immunotoxin against human B cell leukaemias and lymphomas. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -80° C |
| Shipping conditions: | Dry ice |
| References: |
DiJoseph et al. 2006. Clin Cancer Res. 12(1):242-9. PMID: 16397048. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Shen et al. 1988. Int J Cancer. 42(5):792-7. PMID: 3263328. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Bofill et al. 1985. J Immunol. 134(3):1531-8. PMID: 3871452. Campana et al. 1985. J Immunol. 134(3):1524-30. PMID: 3918103. Human B cell development. II. Subpopulations in the human fetus. Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.